Table 3.
Original studies utilizing the da Vinci® Surgical System for multivisceral pelvic exenteration surgery for locally advanced including recurrent rectal cancers
| Author, year | Number of patients | Operation platform | Type of surgery | Mean operating time (h) | Mean blood loss (mL) | Perioperative complications | Mean ITU stay (days) | Hospital stay (days) | Conversion rate (%) | Perioperative complications | Resection margin status (R0) | Recurrence rates |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shin et al., [56] (2014) | 3 | da Vinci | Robotic-assisted | 8.9 (8–9.7) | 530 (300–700) | Vesico-urethral anastomotic leak (1) | NA | 18 (8–28) | NO | NO | 18 (8–28) | 18 (8–28) |
| Nanayakkara et al. [55] (2014) | 1 | da Vinci | Robotic-assisted | NA | NA | NO | NA | 8 | NO | NO | 1/1 (100%) | NA |
| Winters et al. [57] (2015) | 3 | GelPoint Path (daVinci® Si) | Robotic | 10.1 (9.5–11) | 550 (350–800) | NO | 1 | 7 | NO | NO | 1/3 | NA |
| Shin et al., [58] (2016) | 22 | da Vinci | Robotic | 7 (5.5–8.5) | 417.5 (337–496) |
12/22 (52%) Pelvic abscess (4); hemorrhage (1); urinary retention (3); urinary leak (1); ileus (5); re-admissions (6); re-operations (3) |
NA | 4 (3–5.5) | NO | NO | 22/22 (100%) | NA |
| Raj Kumar et al. [59] (2020) | 1 | GelPoint Path (da Vinci® Si) | Robotic | 9 | 750 | NO | NA | NA | NO | NO | 1/1 (100%) | Disease free at 6 months |
| Heah et al. [60] (2020) | 3 | GelPoint Path (daVinci® S) | Robotic-assisted | NA | 700 (600–800) | NO | NA | 12.6 | NO | NO | 2/3 (67%) | NA |
| Smith et al., [61] (2020) | 8 | GelPoint Path (da Vinci® Si=5; Xi=3) | Robotic | 8.3 (6–10) | Received 2 units (2) | NO | 1 (0–3) | 15 (7 to 26) | NO | NO | 8/8 (100%) | Disease free at 12 months |
| Williams et al. [62] (2021) | 5 | GelPoint Path (da Vinci® Si/Xi/S) | Robotic | 7.8 (3–11) | 520 (150–1000) | Mortality (1) | 1 (1–1) | 9 (6–34) | NO | NO | 4/5 (80%) | 3/5 at 21 and 24 months |